BD's Q2 Revenues Drop Slightly While Biosciences Biz Rises 3 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues were down less than 1 percent year over year, but its BD Biosciences segment managed three percent revenue growth for the quarter.

The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.74 billion for the three-month period ended March 31, down from revenues of $1.75 billion in the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.